

Hirokazu Takahashi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5393201/hirokazu-takahashi-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

3,491
citations

29
h-index

57
g-index

86
ext. papers

4,315
ext. citations

5.4
avg, IF

4.5
L-index

#	Paper	IF	Citations
85	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.. <i>Hepatology</i> , 2021 ,	11.2	3
84	Role of vitamin E in the treatment of non-alcoholic steatohepatitis. <i>Free Radical Biology and Medicine</i> , 2021 , 177, 391-403	7.8	1
83	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2275-2284	4.84	6
82	Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. <i>Hepatology Communications</i> , 2021 ,	6	9
81	Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. <i>Hepatology Communications</i> , 2021 , 5, 559-572	6	7
80	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. <i>Diagnostics</i> , 2021 , 11,	3.8	3
79	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040. <i>Hepatology International</i> , 2021 , 15, 366-379	8.8	14
78	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , 2021 , 11,	3	6
77	MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. <i>Hepatology Research</i> , 2021 , 51, 1115-1128	5.1	21
76	Encouraging participation in colorectal cancer screening for people with schizophrenia: A randomized controlled trial. <i>Acta Psychiatrica Scandinavica</i> , 2021 , 144, 318-328	6.5	0
75	The first-round results of a population-based cohort study of HPV testing in Japanese cervical cancer screening: baseline characteristics, screening results, and referral rate. <i>Journal of Gynecologic Oncology</i> , 2021 , 32, e29	4	2
74	Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study. <i>Hepatology Research</i> , 2020 , 50, 955-965	5.1	6
73	Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	20
72	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	22
71	Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020 , 50, 682-692	5.1	22
70	Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. <i>JGH Open</i> , 2020 , 4, 497-502	1.8	12
69	Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. <i>Hepatology Research</i> , 2020 , 50, 831-839	5.1	21

68	Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. <i>Journal of Gastroenterology</i> , 2020 , 55, 428-440	6.9	29
67	Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. <i>Diagnostics</i> , 2020 , 10,	3.8	11
66	Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2020 , 10,	3.8	8
65	Magnetic resonance imaging for the assessment of pathological hepatic findings in nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020 , 47, 535-548	1.4	6
64	Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	11
63	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 1626-1632	4	12
62	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 389-398	18.8	272
61	A randomised controlled trial of a case management approach to encourage participation in colorectal cancer screening for people with schizophrenia in psychiatric outpatient clinics: study protocol for the J-SUPPORT 1901 (ACCESS) study. <i>BMJ Open</i> , 2019 , 9, e032955	3	1
60	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , 2018 , 8, 10434	4.9	25
59	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , 2018 , 53, 1216-1224	6.9	37
58	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. <i>Journal of Gastroenterology</i> , 2018 , 53, 181-196	6.9	46
57	Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms. <i>Frontiers in Endocrinology</i> , 2018 , 9, 588	5.7	25
56	Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. <i>Lancet Oncology</i> , 2016 , 17, 475-483	21.7	180
55	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. <i>Journal of Gastroenterology</i> , 2016 , 51, 586-96	6.9	33
54	Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). <i>Hepatology Research</i> , 2015 , 45, 269-78	5.1	108
53	Association between factors associated with colorectal cancer and rectal aberrant crypt foci in humans. <i>Oncology Letters</i> , 2015 , 10, 3689-3695	2.6	5
52	Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2014 , 44, 812-7	5.1	8
51	Conditional knockout of the leptin receptor in the colonic epithelium revealed the local effects of leptin receptor signaling in the progression of colonic tumors in mice. <i>Carcinogenesis</i> , 2014 , 35, 2134-41	4.6	11

50	Frequency and risk factors for rebleeding events in patients with small bowel angioectasia. <i>BMC Gastroenterology</i> , 2014 , 14, 200	3	23
49	Metabolic factors accelerate colorectal adenoma recurrence. <i>BMC Gastroenterology</i> , 2014 , 14, 187	3	13
48	Characteristics of the small bowel lesions detected by capsule endoscopy in patients with chronic kidney disease. <i>Gastroenterology Research and Practice</i> , 2013 , 2013, 814214	2	7
47	Colon epithelial proliferation and carcinogenesis in diet-induced obesity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28 Suppl 4, 41-7	4	15
46	Factors predicting the presence of small bowel lesions in patients with obscure gastrointestinal bleeding. <i>Digestive Endoscopy</i> , 2013 , 25, 412-20	3.7	29
45	Visceral obesity as a risk factor for left-sided diverticulitis in Japan: a multicenter retrospective study. <i>Gut and Liver</i> , 2013 , 7, 532-8	4.8	18
44	Number of aberrant crypt foci in the rectum is a useful surrogate marker of colorectal adenoma recurrence. <i>Digestive Endoscopy</i> , 2012 , 24, 353-7	3.7	11
43	An epidemiologic survey of chronic intestinal pseudo-obstruction and evaluation of the newly proposed diagnostic criteria. <i>Digestion</i> , 2012 , 86, 12-9	3.6	30
42	Capsule endoscopy with flexible spectral imaging color enhancement reduces the bile pigment effect and improves the detectability of small bowel lesions. <i>BMC Gastroenterology</i> , 2012 , 12, 83	3	26
41	Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. <i>BMC Cancer</i> , 2012 , 12, 118	4.8	44
40	Characteristics of intestinal pseudo-obstruction in patients with mitochondrial diseases. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4557-62	5.6	26
39	Infection of specific strains of <i>Streptococcus mutans</i> , oral bacteria, confers a risk of ulcerative colitis. <i>Scientific Reports</i> , 2012 , 2, 332	4.9	70
38	Increased tumor necrosis factor receptor 1 expression in human colorectal adenomas. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5360-8	5.6	19
37	Relationship of human rectal aberrant crypt foci and formation of colorectal polyp: One-year following up after polypectomy. <i>World Journal of Gastrointestinal Endoscopy</i> , 2012 , 4, 561-4	2.2	5
36	A case of multiple ulcers of the small intestine observed by capsule endoscopy and single-balloon enteroscopy. <i>Progress of Digestive Endoscopy</i> , 2012 , 80, 116-117	0	
35	Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis. <i>Journal of Pharmacological Sciences</i> , 2011 , 115, 270-3	3.7	7
34	Quantitative analysis of low-dose aspirin-associated small bowel injury using a capsule endoscopy scoring index. <i>Digestive Endoscopy</i> , 2011 , 23, 56-61	3.7	12
33	Leptin receptor is involved in STAT3 activation in human colorectal adenoma. <i>Cancer Science</i> , 2011 , 102, 367-72	6.9	15

32	Critical role of aquaporin 3 on growth of human esophageal and oral squamous cell carcinoma. <i>Cancer Science</i> , 2011 , 102, 1128-36	6.9	89
31	The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2011 , 46 Suppl 1, 70-8	6.9	49
30	Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. <i>Journal of Gastroenterology</i> , 2011 , 46, 894-905	6.9	79
29	Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. <i>Gut</i> , 2011 , 60, 1363-71	19.2	106
28	Capsule-endoscopic findings of ulcerative colitis patients. <i>Digestion</i> , 2011 , 84, 306-14	3.6	21
27	Optimal approach for small bowel capsule endoscopy using polyethylene glycol and metoclopramide with the assistance of a real-time viewer. <i>Digestion</i> , 2011 , 84, 119-25	3.6	25
26	Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1918-24	4	26
25	Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. <i>Cancer Prevention Research</i> , 2010 , 3, 1077-83	3.2	241
24	PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study. <i>PPAR Research</i> , 2010 , 2010,	4.3	14
23	Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. <i>Hepatology Research</i> , 2010 , 40, 566-73	5.1	100
22	Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 808-14	4	61
21	Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. <i>Molecular Carcinogenesis</i> , 2010 , 49, 662-71	5	138
20	Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. <i>Digestion</i> , 2009 , 79, 44-51	3.6	68
19	Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. <i>Hepatology</i> , 2009 , 50, 772-80	11.2	153
18	Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. <i>Liver International</i> , 2009 , 29, 1078-85	7.9	58
17	Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2009 , 51, 548-56	13.4	69
16	Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2009 , 39, 963-71	5.1	22
15	Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility. <i>Cancer Science</i> , 2008 , 99, 1892-900	6.9	28

14	Metformin suppresses intestinal polyp growth in ApcMin/+ mice. <i>Cancer Science</i> , 2008 , 99, 2136-41	6.9	142
13	Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathway. <i>Journal of Pharmacological Sciences</i> , 2008 , 106, 627-38	3.7	21
12	Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). <i>BMC Gastroenterology</i> , 2008 , 8, 27	3	53
11	Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). <i>BMC Gastroenterology</i> , 2008 , 8, 53	3	60
10	PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells. <i>International Journal of Cancer</i> , 2007 , 120, 702-13	7.5	47
9	Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 3455-64	4	62
8	Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. <i>Journal of Gastroenterology</i> , 2007 , 42, 375-81	6.9	68
7	High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. <i>Journal of Gastroenterology</i> , 2007 , 42, 573-82	6.9	193
6	A case of bleeding jejunal varices following total gastrectomy. <i>Progress of Digestive Endoscopy</i> , 2007 , 70, 76-77	0	
5	A case of primary intestinal GIST diagnosed by double-balloon enteroscope. <i>Progress of Digestive Endoscopy</i> , 2007 , 71, 94-95	0	1
4	Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. <i>Cancer Science</i> , 2006 , 97, 854-60	6.9	28
3	The difficulty in the diagnosis of the pancreatic invasion from extrahepatic bile duct carcinoma due to the coexisting fibrosis even if endoscopic intraductal ultrasonography was performed-a case report. <i>Progress of Digestive Endoscopy</i> , 2006 , 68, 166-167	0	
2	Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. <i>Cancer Research</i> , 2005 , 65, 2251-9	10.1	96
1	A case of successful resection of the islet cell tumor of the pancreas during endoscopic nasopancreatic drainage (ENPD) before the operation. <i>Progress of Digestive Endoscopy</i> , 2005 , 66, 100-101		